Influence of HMG-CoA reductase inhibitors on markers of coagulation, systemic inflammation and soluble cell adhesion

International Journal of Cardiology

Volumn 82, Issue 1, 2002, Pages 25-31

  Bickel, Christoph ^a,b   Rupprecht, Hans J ^a   Blankenberg, Stefan ^a   Espinola Klein, Christine ^a   Rippin, Gerd ^a   Hafner, Gerd ^a   Lotz, Johannes ^a   Prellwitz, Winfried ^a   Meyer, Jürgen ^a  

^a JOHANNES GUTENBERG UNIVERSITY   (Germany)

^b BUNDESWEHRZENTRALKRANKENHAUS KOBLENZ   (Germany)

Author keywords

Cholesterol; HMG CoA; Lipid lowering; Statin therapy

Indexed keywords

ATORVASTATIN; C REACTIVE PROTEIN; CELL ADHESION MOLECULE; CERIVASTATIN; CHOLESTEROL; FLUINDOSTATIN; HIGH DENSITY LIPOPROTEIN; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; INTERLEUKIN 6; LIPID; LOW DENSITY LIPOPROTEIN; MEVINOLIN; PADGEM PROTEIN; PRAVASTATIN; SIMVASTATIN; TRIACYLGLYCEROL; VON WILLEBRAND FACTOR;

ADULT; AGE DISTRIBUTION; AGED; ANGIOGRAPHY; ARTICLE; BLOOD CLOTTING; CHOLESTEROL BLOOD LEVEL; CONTROLLED STUDY; CORONARY ARTERY DISEASE; FEMALE; HEART MUSCLE ISCHEMIA; HOSPITALIZATION; HUMAN; INFLAMMATION; LEUKOCYTE COUNT; LIPID BLOOD LEVEL; LIPOPROTEIN BLOOD LEVEL; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; SEX DIFFERENCE; TRIACYLGLYCEROL BLOOD LEVEL;

AGED; ANTICHOLESTEREMIC AGENTS; BIOLOGICAL MARKERS; CELL ADHESION; CHOLESTEROL, LDL; CORONARY ARTERIOSCLEROSIS; FEMALE; HUMANS; HYDROXYMETHYLGLUTARYL-COA REDUCTASE INHIBITORS; MALE; MIDDLE AGED; VON WILLEBRAND FACTOR;

EID: 0036146332     PISSN: 01675273     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0167-5273(01)00576-9     Document Type: Article

References (33)

1. Current perspectives on statins
2. Are there potential non-lipid-lowering uses of statins?
3. Antiatherothrombotic properties of statins: Implications for cardiovascular event reduction
4. Impact of viral and bacterial infectious burden on long-term prognosis in patients with coronary artery disease
5. Cytomegalovirus infection with interleukin-6 response predicts cardiac mortality in patients with coronary artery disease
6. Unstable angina. A classification
7. Cholesterol reduction yields clinical benefit: Impact of statin trials
8. Systematic review on the risk and benefit of different cholesterol-lowering interventions
9. Users' guides to the medical literature: XIX. Applying clinical trial results B. Guidelines for determining whether a drug is exerting (more than) a class effect
10. Reduced platelet aggregation after fluvastatin therapy is associated with altered platelet lipid composition and drug binding to the platelets
11. Interactions of platelets, macrophages, and lipoproteins in hypercholesterolemia: Antiatherogenic effects of HMG-CoA reductase inhibitor therapy
12. Pravastatin therapy in hyperlipidemia: Effects on thrombus formation and the systemic hemostatic profile
13. HMG-CoA reductase inhibition by atorvastatin reduces neointimal inflammation in a rabbit model of atherosclerosis
14. HMG-CoA reductase inhibitors reduce MMP-9 secretion by macrophages
15. Simvastatin, an HMG-coenzyme A reductase inhibitor, improves endothelial function within 1 month
16. Effect of pravastatin on outcomes after cardiac transplantation
17. Role of mevalonic acid in the regulation of natural killer cell cytotoxicity
18. Reversal of lovastatin-mediated inhibition of natural killer cell cytotoxicity by interleukin 2
19. Leukocyte trafficking mediated by selectin-carbohydrate interactions
20. Leukocyte rolling and extravasation are severely compromised in P selectin-deficient mice
21. Simvastatin preserves the ischemic-reperfused myocardium in normocholesterolemic rat hearts
22. Impact of preexisting statin use on adhesion molecule expression in patients presenting with acute coronary syndromes
23. Statins and cardiovascular diseases: The multiple effects of lipid-lowering therapy by statins
24. Fluvastatin reduces soluble P-selectin and ICAM-1 levels in hypercholesterolemic patients: Role of nitric oxide
25. Reduction of serum cholesterol levels alters lesional composition of atherosclerotic plaques. Effect of pravastatin sodium on atherosclerosis in mature WHHL rabbits
26. Effect of cerivastatin sodium, a new inhibitor of HMG-CoA reductase, on plasma lipid levels, progression of atherosclerosis, and the lesional composition in the plaques of WHHL rabbits
27. Pravastatin has cholesterol-lowering independent effects on the artery wall of atherosclerotic monkeys
28. Long-term effects of pravastatin on plasma concentration of C-reactive protein
29. Measurement of C-reactive protein for the targeting of statin therapy in the primary prevention of acute coronary events
30. Rapid reduction in C-reactive protein with cerivastatin among 785 patients with primary hypercholesterolemia
31. Prospective study of hemostatic factors and incidence of coronary heart disease: The Atherosclerosis Risk in Communities (ARIC) Study
32. Early increase of von Willebrand factor predicts adverse outcome in unstable coronary artery disease: Beneficial effects of enoxaparin
33. Statin therapy, lipid levels, C-reactive protein and the survival of patients with angiographically severe coronary artery disease